Micardis HCT

Micardis HCT is a brand name of hydrochlorothiazide/telmisartan, approved by the FDA in the following formulation(s):

MICARDIS HCT (hydrochlorothiazide; telmisartan - tablet; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: November 17, 2000
  
  Strength(s): 12.5MG;40MG, 12.5MG;80MG
  


• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: April 19, 2004
  
  Strength(s): 25MG;80MG ^[RLD]

Has a generic version of Micardis HCT been approved?

No. There is currently no therapeutically equivalent version of Micardis HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Micardis HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Benzimidazoles useful as angiotensin-11 antagonists
  Patent 5,591,762
  Issued: January 7, 1997
  Inventor(s): Hauel; Norbert & Narr, deceased; Berthold & Ries; Uwe & van Meel; Jacobus C. A. & Wienen; Wolfgang & Entzeroth; Michael
  Assignee(s): Dr. Karl Thomae GmbH
  Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.
  
  Patent expiration dates:
  
  
  • January 7, 2014
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Polymorphs of telmisartan
  Patent 6,358,986
  Issued: March 19, 2002
  Inventor(s): Heinrich; Schneider
  Assignee(s): Boehringer Ingelheim Pharma KG
  The invention relates to polymorphs of 4′-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.
  
  Patent expiration dates:
  
  
  • January 10, 2020
    
  
  

See also...

• Micardis HCT Consumer Information (Wolters Kluwer)
• Micardis HCT Consumer Information (Cerner Multum)
• Micardis HCT Advanced Consumer Information (Micromedex)
• Hydrochlorothiazide/Telmisartan Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and telmisartan Consumer Information (Cerner Multum)
• Telmisartan and hydrochlorothiazide Advanced Consumer Information (Micromedex)